



Interim report 2nd half year 2022 for Icecat N.V.

This report has not been audited by an external auditor.

Management board report

Key financials

The revenues of Icecat N.V. (ISIN: NL0012751226) have increased by 8% over the second six months of 2022 to 6.2 million euro compared to the same period last year.

Also the gross profit increased over the same period by 9%. Due to rather stable operating expenses, the EBT increased by 40% to 1.3 million euro. These earnings contribute to the already very solid cash position.

We maintained growth of the business, despite a post-pandemic cooldown in the e-commerce market and recession fears, and we strive to maintain or further improve growth during 2023. We can pass on the inflationary pressure to our clients. It is unclear whether a general recession might become reality in major Western markets and how severe this might be. Nevertheless, the outlook for our product information management services appears to remain solid.

We didn't have merger & acquisition activities in this period, other than continuously evaluating investment opportunities.

Non-financial KPIs

The COVID-19 lockdowns are accompanied by a quickened adoption of e-commerce, which is visible in our online footprint: the number of product data sheet (PDS) downloads during H2-2022 increased by 33% to 10.2 billion compared to the same period one year earlier. Icecat's data-sheet production increased by 19% to 1.2 million new product data-sheets, and the database contains now more than 13 million product data-sheets, each available in around 60 languages. The average number of monthly brand-type users has increased by 8% to 2,945. These trends imply that the relevance of Icecat has further increased.

2023 developments

One of the most exciting developments of 2023 are the release of a new Open AI framework and ChatGPT, given the many possible applications within Icecat as a publisher of structured data.

Generating tip texts for consumers is a good example: <https://iceclog.com/chatgpt-is-perfect-for-producing-tip-texts-for-specs/>.

Another potential gamechanger for Icecat is the current window of opportunity in the US because of challenges that our main US competition experiences.

Board

All board members remained in post.

Martijn Hoogeveen
MD/CEO

Emre Tan
MD/Chief Growth Officer

Amsterdam, January 31, 2023

Statement of income and expenses and other comprehensive income for the second half year 2022 in euro

	<u>H2-2022</u>	<u>H2-2021</u>
Net turnover	6,233,841	5,775,543
Cost of sales	429,038	432,067
Gross profit	5,804,802	5,343,476
Personnel expenses	2,591,246	2,602,845
Depreciation of tangible fixed assets	66,898	65,602
Other operating expenses	1,789,434	1,697,139
Total operating expenses	4,447,579	4,365,586
Operating result	1,357,224	977,890
Interest and similar expenses	-10,483	-18,474
Financial income and expense	-10,483	-18,474
Result from operational activities before taxation	1,346,741	959,416
Share in result from participations	0	25,890,325
Net consolidated result before taxation	1,346,741	26,849,741

These figures are before taxation

INVESTMENT DISCLAIMER

Important information

This report (the “Document”) contains a description of some important subjects regarding Icecat N.V. (alone or together with her daughter companies, “Icecat” or “Company”). This Document, which is not complete, is distributed in behalf of Icecat and Icecat is responsible for the accuracy of information included. The information contained in this Document is accurate only as of the date of this Document, regardless of the time of delivery of the Document. Icecat however, points out that this Document gives only a limited view of its activities and its subsidiaries. Therefore, this document is an inappropriate basis for taking a decision to invest in the depository receipts of ordinary shares of Icecat as issued by Stichting Administratiekantoor Icecat (the “DRs”), and as currently listed at NPEX. Regarding the decision to buy or sell DRs, a potential investor should exclusively base himself or herself on information included in the prospectus, and all subsequently distributed information, and not just on information in this Document. Market information or expectations or forward looking statements in so far expressed in this Document don’t form a sound basis for investment decisions. This Document doesn’t form an offer or an invitation to buy DRs, in particular the (citizens and territories of the) United States, Canada, Japan and Australia are excluded. The DRs are not allowed to be offered or sold in the United States or in behalf of persons in the United States as defined in Regulation S conforming to the U.S. Securities Act 1933, as changed (“Securities Act”), unless they are registered conforming the Securities Act or are exempted from registration under any exception term to it. Icecat has not registered DRs as such and is not planning an initial public offering of DRs of Shares in the United States.

Investment Risks

Investing in products like (depository receipts of) shares involves risks. The results of the company or companies in which you invest can be disappointing. This is also true for the results of Icecat. The DRs might not be tradable on a public market, and there might not be an active and liquid market for the DRs. Further, there is the possibility that you will not receive dividends. Potential investors, before deciding to buy Depository Receipts, should read the prospectus and subsequent communications carefully. In particular, they should read the sections related to risks in investing in the DRs, as included in the chapter “Risk Factors” of the prospectus. Before a potential investor decides to trade DRs, it is advised to consult a professional financial advisor. This Document contains statements about the future that are based on current strategies, and current strategies, assessments, and expectations about the future of Icecat with regard to external developments. These statements will include assumptions, risks and uncertainties, that can change after the date of publication of this Document.

The value of your investment in DRs can fluctuate. Results of the past, don’t provide a guarantee for future results. For further information, please see <https://www.npex.nl/>.